# Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors

> **NCT02034708** · PHASE4 · COMPLETED · sponsor: **Guerbet** · enrollment: 279 (actual)

## Conditions studied

- Primary Brain Tumor

## Interventions

- **DRUG:** Dotarem®
- **DRUG:** Gadovist®/Gadavist®

## Key facts

- **NCT ID:** NCT02034708
- **Lead sponsor:** Guerbet
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 279 (ACTUAL)
- **Last updated:** 2016-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02034708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02034708, "Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02034708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*